The Effect of Lactoferrin and Dosing Regimen on Iron Absorption From a Maize-based Porridge in Kenyan Infants

Iron-deficiency Clinical Trial

Official title:

The Effect of Apo- and Holo-Lactoferrin and Dosing Regimen on Iron Absorption From a Maize-based Porridge in Kenyan Infants

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03617575
• Other study ID #: Fe_LF
• Status: Completed
• Phase: N/A
• Start date: December 11, 2018
• Est. completion date: March 30, 2019

Study information

• Verified date: May 2020
• Source: Swiss Federal Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to measure iron absorption from maize-based porridge fortified with either apo-lactoferrin, holo-lactoferrin or ferrous sulfate and to test whether there is an effect of these. Additionally, iron absorption from maize-based porridge containing 12 mg ferrous sulfate will be measured when consumed every other day versus every third day.

Description:

Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia (IDA), which adversely affects their growth and cognitive development. In-home iron fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA by ensuring that the iron needs of infants and young children are met without changing their traditional diet. Oral iron syrups, typically containing iron as ferrous sulfate, can also be given to prevent/correct IDA. However, iron absorption from MNPs and iron syrups, particularly when given with complementary foods high in inhibitors of iron absorption, is low. Thus, there is a need to find iron formulations with higher bioavailability for use in African infants. In a recent trial in Kenya, the investigators demonstrated that a prebiotic could improve iron bioavailability from an iron-containing MNP.

In this study, the investigators plan to assess the human milk compound lactoferrin (Lf) as a possible enhancer of iron absorption. Lf is an important iron-binding protein in human milk, which has been thought to be responsible for the high bioavailability of breast-milk iron. It has many biological functions, including iron absorption, antimicrobial activity, immunomodulatory effects and stimulatory effect on cell proliferation. Lf has different iron binding statuses: the iron free form (apo-Lf) and the iron-saturated form (holo-Lf). One of the two main biological activities of Lf provided by the diet is the control of iron uptake, which is mediated by the Lf receptor (LFR) as undigested Lf can bind to LFR and facilitate the uptake of iron. Therefore, Lf may be a nutritional iron source and may enhance iron absorption in infants. To evaluate the possible role of Lf on the availability of iron, iron absorption will be measured from bovine Lf (bLf). BLf has GRAS (generally considered as safe) status by the US Food and Drug Administration.

To optimize iron absorption, timing of supplementation might as well be important. Hepcidin, a key regulator of systemic iron balance and a single dose of iron can increase hepcidin levels and potentially inhibit iron absorption from a second dose, consumed close in time to the first dose. The investigators will conduct two studies, where 24 infants aged 3-14 months in Msambweni, Kenya, will be enrolled. In study 1, on three alternate mornings, these infants will consume maize porridge containing a low iron dose (1.5 mg) to compare iron absorption between meals with apo-Lf, holo-Lf and ferrous sulfate (FeSO4) as a reference; and whether the addition of either apo- or holo-Lf has a beneficial effect on iron absorption. The investigators hypothesize that iron absorption will be higher when holo-Lf is present in the meal compared to apo-Lf. In study 2, the investigators want to compare two different dosing regimens, in which they measure iron absorption after one-day washout period and after a two-day washout period, and hypothesize that absorption will be higher after 2 days of washout.

The data from this project will provide valuable information towards the development of new, highly bioavailable iron formulations and dosing regimen that is most efficient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: March 30, 2019
• Est. primary completion date: March 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 3 Months to 14 Months

Eligibility

Inclusion Criteria:

• Age of 3-14 months at baseline

• Complementary feeding of the infant has already started

• Assessment of good health as assessed by professional staff at Msambweni District Hospital

• The caregiver is willing to participate in the study

• The informed consent form has been read and signed by the caregiver (or has been read out to the caregiver in case of illiteracy)

• Willingness of the caregiver to provide five blood samples from their child in total during the studies during the visits at the hospital

• Residence in the study for the period of the study

Exclusion Criteria:

• Hb <70 g/L

• Severe underweight (waz <-3)

• Severe wasting (whz <-3)

• Chronic or acute illness or other conditions that in the opinion of the principle investigator or co-researchers would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol

• Participants taking part in other studies requiring the drawing of blood

• Regular intake (>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months

Related Conditions & MeSH terms

• Anemia, Iron-Deficiency
• Iron-deficiency

Intervention

Dietary Supplement:
• apo-Lactoferrin
1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf [total of 1.5 mg iron]) in a maize porridge (extrinsically labeled)
• holo-Lactoferrin
1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
• FeSO4
1.5 mg FeSO4 as 54Fe in a maize porridge
• 1. FeSO4
10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
• FeSO4 after 1 day break
10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
• FeSO4 after 2 day break
10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period

Locations

Country	Name	City	State
Kenya	Msambweni County Referral Hospital	Msambweni	Kwale County

Sponsors (1)

Lead Sponsor	Collaborator
Swiss Federal Institute of Technology

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fractional iron absorption (%)	Fractional iron absorption from 3 different test meals (apo-, holo-Lactoferrin and FeSO4) erythrocyte incorporation of stable iron isotopes into red blood cells 14 days after test meal	Day 21
Secondary	Fractional iron absorption (%)	Fractional iron absorption after 2 different washout periods after receiving test meals (1 day vs 2 days)	Day 41
Secondary	Hemoglobin in g/dL (in blood)	to identify anemia	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41
Secondary	Plasma ferritin in µg/L (in blood)	to identify iron deficiency	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41
Secondary	Soluble transferrin receptor in mg/L (in blood)	to identify iron deficiency	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41
Secondary	C-reactive protein in mg/L (in blood)	to identify acute inflammation, which inhibits iron absorption	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41
Secondary	alpha-1-glycoprotein in g/L (in blood)	to identify chronic inflammation, which inhibits iron absorption	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41
Secondary	Plasma hepcidin (in blood)	one of major iron absorption regulators	Baseline, Day 21, Day 24 (after 1 day washout), Day 27 (after 2 days washout), Day 41